Published in Health and Medicine Week, January 5th, 2004
The results of BCIRG 001, the first phase III study evaluating Taxotere after breast surgery, were presented at the San Antonio (Texas) Breast Cancer Symposium by the Breast Cancer International Research Group. .
"Taxotere continues to demonstrate its effectiveness across various stages of breast cancer, and this study indicates that women with early stage breast cancer and their physicians...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health and Medicine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.